Use of Sotatercept in France since Its Availability in June 2024: A Nationwide Study from the French Health Data System (SNDS).
BACKGROUND Pulmonary arterial hypertension (PAH) is a rare, severe and progressive disease associated with poor quality of life and high mortality. Sotatercept, a first-in-class fusion protein, has recently been shown to provide substantial clinical benefit as add-on therapy in PAH and was made available in France in 2...